Trial Profile
A Phase I/IIa, Open Label, Multiple Site Clinical Trial Evaluating the Safety and Activity of Engineered Autologous T Cells Expressing an Affinity-enhanced TCR Specific for NY-ESO-1 and LAGE-1 in Patients With Relapsed or Progressive Disease in Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Letetresgene autoleucel (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Adaptimmune
- 28 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 28 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 09 Jun 2016 Status changed from recruiting to active, no longer recruiting.